Published in Vaccine Weekly, September 7th, 1998
Such strategies would block or down-regulate the CCR5 chemokine receptor needed for macrophage-tropic (M-tropic) HIV-1 strains to infect cells. M-tropic strains are responsible for the vast majority of HIV infections.
People homozygous for a naturally occurring mutation that inactivates the CCR5 receptor resist HIV infection and appear healthy. Researchers are thus seeking a drug or immune therapy that would reproduce this condition. But a new study shows that people with the CCR5-delta32/delta32 mutation are at increased risk of hypertension, and that they appear to have...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Vaccine Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.